HIMSHims & Hers Health shows strong recent growth and improving profitability, supported by positive thematic trends in digital health. However, valuation metrics are high, and technical indicators suggest some short-term caution.
Hims & Hers is well-positioned in the growing telehealth and personalized wellness sectors, benefiting from increased consumer adoption of digital health solutions.
Hims & Hers shows strong revenue growth and a positive turnaround in profitability, with a solid balance sheet and improving cash flow generation.
The stock has shown strong recent performance, but some indicators suggest it may be approaching overbought territory, hinting at potential for a short-term pause or retracement.
| Factor | Score |
|---|---|
| Digital Health Adoption | 85 |
| Personalized Wellness Market | 70 |
| Subscription Model Strength | 78 |
| Competitive Landscape | 65 |
| Regulatory Environment | 72 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 70 |
| Growth | 95 |
| Balance Sheet Health | 85 |
| Cash Flow | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 65 |
| Volume Confirmation | 75 |
| Support & Resistance | 70 |
| Short-Term Indicators | 80 |
Consistent EPS Beat
The company has exceeded earnings per share (EPS) estimates for the last 4 consecutive quarters, indicating strong operational execution and profitability.
Growth Exceeds P/E
The trailing P/E ratio of 84.29 is high, but the consistent EPS growth suggests potential justification. The company's focus on expanding services and market reach may support this valuation.
High P/E Ratio
The trailing P/E ratio of 84.29 is significantly higher than historical averages and industry peers, suggesting potential overvaluation and a higher risk of price correction.
Negative Net Margins in Prior Years
While current net margins are positive, the company experienced negative net margins in 2023, 2022, and 2021, indicating historical profitability challenges.
August 2025
5
Next Earnings Date
H: $0.27
A: $0.22
L: $0.18
H: 563.59M
A: 551.30M
L: 540.01M
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
49.20 USD
The 39 analysts offering 1 year price forecasts for HIMS have a max estimate of 85.00 and a min estimate of 28.00.